护肾！司美格鲁肽新增慢性肾脏病适应症，中国目前首个且唯一

Core Viewpoint - The approval of Semaglutide (Novo Nordisk's injection) for chronic kidney disease (CKD) in China marks it as the first and only GLP-1 receptor agonist (GLP-1RA) approved for reducing the risk of eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and CKD [2][3]. Summary by Sections Clinical Trials and Efficacy - The FLOW clinical trial demonstrated that Semaglutide at a dose of 1.0 mg significantly reduced the risk of kidney disease progression and cardiovascular and kidney-related deaths by 24% compared to placebo, achieving its primary endpoint [5]. - A meta-analysis involving 85,373 participants showed that GLP-1 receptor agonists reduced the risk of kidney failure by 16%, kidney function deterioration by 22%, and overall risk of death due to kidney disease by 19% [6][8]. Cardiovascular Benefits - GLP-1 receptor agonists were found to lower the risk of cardiovascular death, non-fatal heart attacks, and non-fatal strokes by 14%, with a 13% reduction in all-cause mortality [9]. Clinical Guidelines Impact - The findings from these studies are expected to significantly influence clinical guidelines for managing chronic kidney disease and cardiovascular diseases in both diabetic and non-diabetic patients [11]. Combination Therapy - A recent study published in J Diabetes Investig indicated that the combination of GLP-1RA and SGLT-2i significantly reduced the risk of major adverse kidney events by 27% compared to SGLT-2i alone, with a notable 46% reduction in all-cause mortality risk [13][16]. Safety Profile - The combination therapy showed an increased incidence of dermatitis/eczema and hypoglycemia, but a lower risk of electrolyte imbalance compared to SGLT-2i monotherapy [17].